Goldman Sachs lowers Corteva stock price target to $20 post-spinoff
Goldman Sachs reduced its price target for Corteva (CTVA) to $20 from $96, maintaining a Buy rating. The company spun off its seed business, Vylor, on October 1, 2026. Corteva shares are at $14.45, up 15% in a week. Goldman values Corteva at 10.5x EV/EBITDA, projecting $600M annual free cash flow in 2027-29. Other analysts have also adjusted targets post-spinoff.
How this was made
The 30-second read
Why it matters
The consensus of analyst downgrades signals a near‑term bearish bias for Corteva, though the company retains a solid balance sheet and cash flow generation.
Market read
Analyst target cuts are a primary catalyst for short‑term price moves, making this a noteworthy event for traders.
What to watch
Potential upside from cost‑saving synergies after the spin‑off and a strong free‑cash‑flow outlook could support a higher valuation.
Background
Corteva completed the spin‑off of its seed business Vylor on Oct 1, separating two‑thirds of its sales and EBITDA. Multiple analysts have revised targets in response.
Ticker impact
Goldman Sachs lowered its price target on Corteva to $20, down from $96, after the recent spinoff of its seed business.
likely pressure as the market prices in the lower valuation and target
The target cut is substantial (38% upside removed) and comes from a major sell‑side firm, prompting traders to reassess valuation.
Market effects
The downgrade may weigh on the broader crop‑chemical sector as peers are re‑valued post‑spinoff.
U.S. agribusiness investors could see modest sell‑off pressure.
Limited to investors tracking agricultural inputs and fertilizer markets.
Counterpoint
Some investors may view the lower target as an opportunity, betting the market overreacted to the spinoff.
Key entities
- AnalystGoldman Sachs
Reduced Corteva price target to $20.
- CompanyCorteva Inc.
Agricultural chemicals firm undergoing a major spin‑off.
